AKT1 and acute lymphoblastic leukemia: Although several preclinical studies indicated that inhibition of PI3K/Akt/mTOR signaling could be an effective treatment for targeted therapy of T-ALL [13], it is still unclear which is the best target in this highly complex and branched signaling network.